Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy.
作者信息
Dhakal Binod, Abedin Sameem, Fenske Timothy, Chhabra Saurabh, Ledeboer Nathan, Hari Parameswaran, Hamadani Mehdi
机构信息
Blood and Marrow Transplant and Cellular Therapy Program, Department of Medicine, and.
Department of Pathology and Laboratory Medicine, Medical College of Wisconsin, Milwaukee, WI.
出版信息
Blood. 2021 Oct 7;138(14):1278-1281. doi: 10.1182/blood.2021012769.
Abstract
摘要
相似文献
1
Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy.造血细胞移植和嵌合抗原受体T细胞疗法后患者对SARS-CoV-2疫苗接种的反应。
Blood. 2021 Oct 7;138(14):1278-1281. doi: 10.1182/blood.2021012769.
2
Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.造血干细胞移植和嵌合抗原受体 T 细胞治疗受者对 SARS-CoV-2 疫苗接种的免疫反应。
J Hematol Oncol. 2022 Jun 16;15(1):81. doi: 10.1186/s13045-022-01300-9.
3
Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy.造血细胞移植和嵌合抗原受体 T 细胞治疗后对 SARS-CoV-2 疫苗的体液反应的预测因素。
Blood Cancer Discov. 2021 Sep 13;2(6):577-585. doi: 10.1158/2643-3230.BCD-21-0142. eCollection 2021 Nov.
4
Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies.接受B细胞定向疗法的淋巴瘤患者对新冠疫苗接种的体液免疫反应受损。
Blood. 2021 Sep 2;138(9):811-814. doi: 10.1182/blood.2021012443.
5
SARS-COV-2 vaccination after stem cell transplantation for scleroderma.硬皮病干细胞移植后的新型冠状病毒 2 型疫苗接种
Ann Rheum Dis. 2021 Oct;80(10):1354-1355. doi: 10.1136/annrheumdis-2021-220677. Epub 2021 May 28.
6
SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.造血干细胞移植受者接种 SARS-CoV-2 疫苗后针对 SARS-CoV-2 的抗体检测：来自西班牙造血干细胞移植和细胞治疗组的前瞻性调查。
Am J Hematol. 2022 Jan 1;97(1):30-42. doi: 10.1002/ajh.26385. Epub 2021 Nov 2.
7
Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.接受CAR T细胞疗法治疗的患者接种一剂和/或两剂BNT162b2抗SARS-CoV-2 mRNA疫苗后的安全性和抗体反应。
Br J Haematol. 2022 Jan;196(2):360-362. doi: 10.1111/bjh.17818. Epub 2021 Sep 2.
8
Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology. 关于造血细胞移植和嵌合抗原受体 T 细胞受者的 2019 年冠状病毒病疫苗接种的常见问题解答（来自美国移植和细胞治疗学会与美国血液学会）。
Transplant Cell Ther. 2023 Jan;29(1):10-18. doi: 10.1016/j.jtct.2022.10.010. Epub 2022 Oct 21.
9
Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation.异基因造血干细胞移植后患者体液免疫对 COVID-19 疫苗接种的反应的影响因素和特征。
Front Immunol. 2023 May 3;14:1174289. doi: 10.3389/fimmu.2023.1174289. eCollection 2023.
10
Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.新型冠状病毒对造血干细胞移植和嵌合抗原受体 T 细胞治疗受者的影响。
Transplant Cell Ther. 2021 Sep;27(9):796.e1-796.e7. doi: 10.1016/j.jtct.2021.07.005. Epub 2021 Jul 10.
引用本文的文献
1
Advances in brain-targeted delivery strategies and natural product-mediated enhancement of blood-brain barrier permeability.脑靶向递送策略及天然产物介导增强血脑屏障通透性的研究进展。
J Nanobiotechnology. 2025 May 26;23(1):382. doi: 10.1186/s12951-025-03415-w.
2
Mitigating and managing infection risk in adults treated with CAR T-cell therapy.减轻和管理接受CAR T细胞疗法治疗的成人的感染风险。
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):116-125. doi: 10.1182/hematology.2024000535.
3
Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients.与mRNA疫苗相比，ChAdOx1-S（AZD1222）疫苗接种后造血细胞移植受者体内的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）中和抗体反应保留得更多。
Br J Haematol. 2024 Dec;205(6):2206-2218. doi: 10.1111/bjh.19874. Epub 2024 Nov 17.
4
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19.曲折之路：COVID-19 时代 CAR-T 及其他新型过继性细胞疗法的传染病考量
Semin Hematol. 2024 Oct;61(5):321-332. doi: 10.1053/j.seminhematol.2024.08.002. Epub 2024 Aug 23.
5
COVID-19 and Cancer Care: A Review and Practical Guide to Caring for Cancer Patients in the Era of COVID-19.COVID-19 与癌症护理：COVID-19 时代癌症患者护理的综述与实用指南。
Curr Oncol. 2024 Sep 10;31(9):5330-5343. doi: 10.3390/curroncol31090393.
6
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group.随着时间的推移，接受 CAR T 细胞治疗的 COVID-19 患者的预后得到改善：代表欧洲血液和骨髓移植学会（EBMT）传染病工作组（IDWP）和欧洲血液学协会（EHA）淋巴瘤小组进行的欧洲 COVID-19 多中心研究的更新。
Leukemia. 2024 Sep;38(9):1985-1991. doi: 10.1038/s41375-024-02336-1. Epub 2024 Jul 23.
7
Infections associated with CAR-T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies.与复发难治性多发性骨髓瘤患者接受嵌合抗原受体 T 细胞（CAR-T）疗法相关的感染：风险和预防策略。
Cancer Med. 2024 Jun;13(12):e7372. doi: 10.1002/cam4.7372.
8
Cellular and humoral immunogenicity against SARS-CoV-2 vaccination or infection is associated with the memory phenotype of T- and B-lymphocytes in adult allogeneic hematopoietic cell transplant recipients.细胞和体液免疫原性针对 SARS-CoV-2 接种或感染与成年异基因造血细胞移植受者的 T 和 B 淋巴细胞记忆表型相关。
Int J Hematol. 2024 Aug;120(2):229-240. doi: 10.1007/s12185-024-03802-3. Epub 2024 Jun 6.
9
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.异基因造血细胞移植或嵌合抗原受体 T 细胞治疗后第一年的 SARS-CoV-2 疫苗接种：一项前瞻性、多中心、观察性研究。
Clin Infect Dis. 2024 Aug 16;79(2):542-554. doi: 10.1093/cid/ciae291.
10
Impact of Prior COVID-19 Immunization and/or Prior Infection on Immune Responses and Clinical Outcomes.既往 COVID-19 免疫接种和/或既往感染对免疫应答和临床结局的影响。
Viruses. 2024 Apr 26;16(5):685. doi: 10.3390/v16050685.
本文引用的文献
1
Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients.mRNA-1273 新型冠状病毒疫苗在肾移植受者中的细胞和体液反应。
Am J Transplant. 2021 Aug;21(8):2727-2739. doi: 10.1111/ajt.16701. Epub 2021 Aug 4.
2
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.第五周抗 SARS-CoV-2 BNT162b2 疫苗在接受积极治疗的多发性骨髓瘤和骨髓增生性恶性肿瘤患者中的免疫原性和安全性：来自单一机构的初步数据。
J Hematol Oncol. 2021 May 17;14(1):81. doi: 10.1186/s13045-021-01090-6.
3
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.2019冠状病毒病疫苗对慢性淋巴细胞白血病患者的疗效
Leukemia. 2021 Sep;35(9):2703-2705. doi: 10.1038/s41375-021-01270-w. Epub 2021 May 13.
4
Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma.多发性骨髓瘤患者对严重急性呼吸综合征冠状病毒2首次疫苗接种的反应。
Lancet Haematol. 2021 Jun;8(6):e389-e392. doi: 10.1016/S2352-3026(21)00110-1. Epub 2021 Apr 19.
5
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.骨髓瘤老年患者在接种第一剂BNT162b2疫苗后对新冠病毒的中和抗体反应较低。
Blood. 2021 Jul 1;137(26):3674-3676. doi: 10.1182/blood.2021011904.
6
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.BNT162b2 mRNA新冠疫苗在慢性淋巴细胞白血病患者中的疗效
Blood. 2021 Jun 10;137(23):3165-3173. doi: 10.1182/blood.2021011568.
7
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients.mRNA 疫苗在实体器官移植受者中的单剂免疫原性。
JAMA. 2021 May 4;325(17):1784-1786. doi: 10.1001/jama.2021.4385.
8
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.基于 rAd26 和 rAd5 载体的异源初免-加强型 COVID-19 疫苗的安全性和有效性：俄罗斯一项随机对照 3 期临床试验的中期分析。
Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2.
9
Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical Evaluation.抗SARS-CoV-2抗体的定量检测：分析与临床评估
J Clin Microbiol. 2021 Mar 19;59(4). doi: 10.1128/JCM.03149-20.
10
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.Ad26.COV2.S 新冠疫苗 1/2a 期临床试验的中期结果。
N Engl J Med. 2021 May 13;384(19):1824-1835. doi: 10.1056/NEJMoa2034201. Epub 2021 Jan 13.
Zotero 插件